LONDON (Thomson Financial) - EiRx Therapeutics PLC posted a narrower first
half pretax loss on lower administrative expenses and said it is reviewing
options including partnering with larger businesses and merger and acquisitions
opportunities for product development.
The drug discovery company developing targeted therapies for cancer said
pretax loss for the six months ended Dec 31, 2007 narrowed to 514,907 stg from
restated 892,275 stg last year.
Administrative expenses were down at 546,045 stg from 916,560 stg in the
previous year.
TFN.newsdesk@thomson.com
ukn/jfr
COPYRIGHT
Copyright Thomson Financial News Limited 2008. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|